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Circulating endothelial cells are associated with future vascular
events in hemodialysis patients.
Background. Endothelial dysfunction and injury are thought
to have a key role in the pathogenesis of cardiovascular disease.
We hypothesized that the presence of circulating endothelial
cells, as a reflection of ongoing endothelial injury, might provide
a novel means for predicting cardiovascular events in hemodial-
ysis subjects who are known to be at marked increased risk for
cardiovascular disease.
Methods. Circulating endothelial cell number was deter-
mined in 29 hemodialysis patients who were then followed for
vascular events for 470 ± 172 days. In a second cohort of 44
hemodialysis patients, circulating endothelial cell number was
correlated with markers of inflammation, namely high sensitiv-
ity C-reactive protein (hs-CRP), interleukin (IL)-6, IL-10, and
monocyte chemoattractant protein-1 (MCP-1), and endothe-
lial dysfunction, soluble vascular cellular adhesion molecule-1
(VCAM-1).
Results. Seven of the 19 subjects with elevated circulating en-
dothelial cells (defined as >19 cells per mL) had cardiovascular
(N = 5) or vascular (N = 5) events during follow-up, whereas
no events occurred in subjects with a low number of circulating
endothelial cells (≤19 CECs per mL) (P = 0.04 by Fisher Exact
Test). In the second cohort, the number of circulating endothe-
lial cells was independent of all markers of inflammation and
endothelial dysfunction.
Conclusion. In this hemodialysis population, an increase in
circulating endothelial cells was found to predict the develop-
ment of cardiovascular and vascular events, and to be indepen-
dent of other known markers of inflammation or endothelial
dysfunction. These studies suggest that circulating endothelial
cells may be a novel way to assess endothelial health and car-
diovascular risk. Further studies to investigate the utility of cir-
culating endothelial cells in predicting cardiovascular risk are
needed.
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Patients with end-stage renal disease (ESRD) have a
dramatically increased risk of cardiovascular (CV) dis-
ease. Both traditional risk factors (i.e., hypertension, hy-
perlipidemia, obesity) as well as factors related to uremia
(i.e., anemia, calcium loading, and chronic inflammation)
have been identified as key mediators [1, 2].
The “response to injury” hypothesis proposed by Ross
suggests that the initial event of atherosclerotic disease
is endothelial injury, leading to a local inflammatory re-
sponse with macrophage infiltration, smooth muscle cell
proliferation, and a fibrous cap [3]. The central role of
endothelial injury in the development of atherosclerosis
and vascular disease [4] has prompted the development
of methods to measure endothelial injury and dysfunc-
tion. The ability of the endothelium to release nitric oxide
(reflected by measurement of acetylcholine-dependent
vasodilatation by brachial artery reactivity) [5] or mea-
suring the release of endothelial cell antigens into the
blood (vascular cellular adhesion molecule, etc.) repre-
sent some of the major methods currently used. However,
these measures may be compromised by dietary intake or
the use of medications (that affect NO production) [6],
and in addition, the release of antigens may not necessar-
ily reflect endothelial injury.
We reasoned that, if the end result of a variety of in-
sults, hypertension, hyperlipidemia, oxidative stress, was
endothelial damage, then the number of detached en-
dothelial cells circulating in blood may be a sensitive and
specific measure of endothelial injury. The number of
these detached endothelial cells may not only be a direct
measure of the severity of the insult, but also a direct mea-
sure of the ability of an individual’s endothelium to resist
that insult. We have previously reported that circulating
endothelial cells (CECs) are indeed elevated in subjects
with hypertension, diabetes, and in hemodialysis patients
[7]. Interestingly, not all subjects in these studies had el-
evated CECs. We thus tested the hypothesis that those
subjects who had an elevated CEC number would be at
the greatest risk for CV events. We also determined how
CECs compared as a risk factor with other established
1078
Koc et al: CEC and cardiovascular events 1079
risk factors. We now report in this preliminary study that
in hemodialysis patients elevated CECs are strong pre-
dictors for the development of vascular events, and that
this measurement appears independent of classic CV risk
factors.
METHODS
Patients and subjects
The study protocol was approved by the Institutional
Review Board at the University of Florida, and written
informed consent was obtained from each patient. Pa-
tients were asked to participate without regard to their
cardiovascular disease status. Exclusion criteria for the
hemodialysis patients were (1) signs or symptoms of any
clinical infection during the month previous and month
after the blood draw; (2) patients on glucocorticoids or
anti-inflammatory medications other than aspirin; (3)
central line insertion or any invasive procedure during the
month previous to the blood draw; (4) HIV infection; (5)
hepatitis B or C infection; and (6) active or past history of
neoplastic or rheumatologic disease. Sixteen of the 60 pa-
tients who agreed to participate in the study met exclusion
criteria. The Cohort 2 study population consisted of 44
individuals receiving conventional hemodialysis for four
hours three times weekly. Hemodialysis procedures were
performed using F80 polysulfone dialyzers (Fresenius
Medical Care, Lexington, MA, USA), bicarbonate
dialysate, and heparin sodium as standard anticoagulant.
Seventeen of these patients were among the 29 patients
who previously had undergone CEC enumeration as de-
scribed in our previous study [7]. Twenty-one patients in
the first cohort and 18 patients in the second cohort were
further classified using a modified Index of Co-Existing
Disease (ICED) as previously described [7]. The score
in each category of vascular disease [coronary artery dis-
ease (CAD), cerebral vascular events (CVE), and periph-
eral vascular disease (PVD)] was used to classify patients
into three groups: No-ACVD: ICED score 0 in each of
the three categories and a negative cardiac catheteriza-
tion within the past year. Patients in this category have
no history of any atherosclerotic cardiovascular disease,
and have had a negative cardiac catheterization within
the past year. Stable-ACVD: ICED score of 1 in at least
one category and no ICED score of 2 in any category. Pa-
tients in this category had the diagnosis of atherosclerotic
cardiovascular disease, but have been asymptomatic dur-
ing the three months prior to CEC enumeration. Active-
ACVD: ICED score of 2 in at least one category. Patients
in this category had the diagnosis of atherosclerotic car-
diovascular disease, and were symptomatic during the
three months prior to CEC enumeration.
Eight hemodialysis patients in the first cohort and
25 patients in the second cohort were not included in
this subgroup analysis even though they had no history
of vascular disease because they did not have a recent
(within past year) cardiac catheterization.
Collection of blood specimens
Blood from hemodialysis patients was withdrawn dur-
ing a midweek hemodialysis session into ethylene di-
amine tetra-acetic acid (EDTA)-containing tubes from
the arterial line of hemodialysis sets before the return of
any blood to the systemic circulation. An additional 4 mL
of blood was also withdrawn for separation and storage
of serum and plasma.
Enumeration of circulating endothelial cells
Enumeration was performed as previously described
[7]. Briefly, after lysing red blood cells from 0.5 mL
of whole blood, 1 × 106 immunomagnetic beads (Dyn-
abeads M-500, Dynal Biotech, Inc., Oslo, Norway) con-
jugated with P1H12 (Chemicon, Temecula, CA, USA),
a murine, monoclonal antibody specific for human en-
dothelial cells [8], were used to isolate circulating en-
dothelial cells. The rosetted cells were cytospun onto
poly-L-lysine coated slides. After drying overnight, the
slides were fixed with 1% paraformaldehyde, stained
with 1 lg/mL propidium iodine in phosphate-buffered
saline (PBS), prior to mounting the slides in Vectashield
with DAPI (Vector Laboratories, Inc., Burlingame, CA,
USA). Quantitation of CEC was performed by identifica-
tion of the cells using a Zeiss Axiophot microscope (Carl
Zeiss, Inc., Thornwood, NY, USA).
Access and cardiovascular events
Twenty-nine patients enrolled in our previous study [7]
were followed for an average of 470 ± 172 days (range
40 to 588), and the incidence of access related events,
cardiovascular events, or death was recorded. The de-
termination of cardiovascular and access events were
made blinded to CEC number. Cardiovascular events
were defined as myocardial infarction (1 patient); cardiac
arrest (2 patients); ischemic colitis (1 patient); transient
ischemic attack or cerebrovascular accident (1 patient);
the need for coronary angioplasty or coronary bypass
surgery (0 patients); or the need for peripheral artery
angioplasty, bypass surgery, or amputation due to periph-
eral arterial disease (0 patients). We did not include death
due to sepsis (1 patient, high CEC group), chronic clau-
dication (present before CEC enumeration) secondary
to an old clot in a femoral access (1 patient, low CEC
group), or CHF exacerbation due to increased fluid in-
take (1 patient, high CEC group). Nor did we include a
reversible ischemic defect found on an adenosine thal-
lium done on an asymptomatic patient during transplant
screening (1 patient, high CEC group). Access events
included need for AV fistula angioplasty (4 events in
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3 patients) and access revision (1 patient). We did not
include any angioplasty that was in a fistula that had poor
flows prior to CEC enumeration (1 patient, high CEC
group), or thrombosis of a graft placed after CEC enu-
meration (1 patient, low CEC group).
Laboratory tests
Levels of plasma IL-6, IL-10, MCP-1 (BD Biosciences
Pharmingen, San Diego, CA, USA), and serum solu-
ble VCAM-1 (BioSource International, Inc., Camarillo,
CA, USA) were determined by enzyme-linked im-
munosorbent assay (ELISA). The assays were per-
formed as per manufacturer instructions, and devel-
oped with tetramethylbenzidine dihydrochloride sub-
strate (Pierce, Rockford, IL, USA), and read on a Pow-
erWave 200 Scanning Spectrophotometer (Bio-Tek Inst.,
Winooski, VT, USA). hs-CRP levels were determined on
a BN ProSpec System Nephelometer (Dade Behring,
Deerfield, IL, USA).
Statistical analysis
Statistical analysis was performed with Prism Statis-
tical software (version 3.02; Graphpad, San Diego, CA,
USA). Continuous variables were reported as mean ±
standard deviation unless otherwise specified. Compar-
isons of continuous variables between the groups were
performed by Mann-Whitney U test or unpaired t test
where appropriate. Since MCP-1, hs-CRP, IL-6, and IL-
10 values and IL-6 to IL-10 ratios are non-normally dis-
tributed, they were log transformed, and log transformed
values were used for statistical analysis. The Fisher exact
test was used to compare the categorical variables. Corre-
lation analyses were performed by Spearman’s rank cor-
relation analysis. Multivariate regression analyses were
employed when evaluating the effect(s) of continuous
variables on the number of CECs used as the dependent
variable. Survival curves were calculated by the Kaplan-
Meier method, and compared by log rank test using SAS
(version 8.02, Cary, NC, USA). Results were regarded as
significant at P < 0.05.
RESULTS
Cohort 1: Elevated CECs predict vascular events in
hemodialysis subjects
We previously described CEC enumeration in 29
hemodialysis patients [7]. These patients had a mean CEC
number of 31 ± 19 per mL compared to the mean of
healthy control patients of 19 ± 7 per mL [7]. Given our
normal mean of 19 cells per mL in healthy subjects, we
used the CEC cutoff of 19 cells per mL to categorize pa-
tients into high (N = 19) and low (N = 10) CEC number
groups. Table 1 shows the baseline characteristics in these
two subgroups in terms of dialysis adequacy, presence
of established CV risk factors, and use of angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin II re-
ceptor blocker (ARB) and HMG CoA reductase therapy.
There were 7 patients with hypertension and 4 patients
with glomerulonephritis as the etiology of their ESRD.
The mean number of CECs among patients with hyper-
tension (30 ± 8.9) was similar (P = 0.20) to the mean
number of CECs among patients with glomerulonephri-
tis (33 ± 34.0) as the etiology of their ESRD. There was
also no statistical difference in the number of patients
with hypertension or glomerulonephritis in the high and
low CEC groups (Table 1). In the first cohort we found a
higher calcium phosphorous product in the higher CEC
group (Table 1). However, while evaluating all hemodial-
ysis patients in cohort 1 and 2 as a whole, we did not find a
correlation between CEC number and calcium phospho-
rous product (data not shown).
Patients were followed for a mean of 470 ± 172 days
(range 40 to 588 days). All five cardiovascular events (2
cardiovascular deaths, 1 myocardial infarction, 1 cerebral
vascular accident, 1 ischemic colitis) and five access re-
lated events (4 angioplasties and 1 arteriovenous fistula
revision) occurred in patients with an elevated CEC num-
ber (P = 0.04 by Fisher exact test). Using Kaplan-Meier
plot, a 30% difference in morbidity and mortality be-
tween the two groups was observed at 20 months (Fig. 1,
P = 0.035). The Kaplan-Meier plots showed a trend to-
ward more cardiovascular events (P = 0.085) in patients
who had greater than 19 CECs per mL (Fig. 1). The seven
patients who had an event had a statistically higher CEC
number than all of the rest of the patients (44.3 ± 22.6 vs.
26.5 ± 16.4; P = 0.03 by Student t test).
Cohort 2: Correlation of CECs with inflammation and
endothelial dysfunction
In the original study, a correlation of CECs with mark-
ers of systemic inflammation and endothelial dysfunction
had not been performed. We therefore studied a second
cohort (44 subjects) on hemodialysis, and measured clas-
sical markers of inflammation (hs-CRP, IL-6, and MCP-
1), anti-inflammation (IL-10), and endothelial dysfunc-
tion (serum VCAM-1), and evaluated their relationship
with the number of CECs.
Baseline characteristics of the new and old patient co-
hort are shown in Table 1. Of the 44 hemodialysis sub-
jects, 22 had an elevated CEC number (above 19 cells per
mL), and 22 had a low CEC number (19 cells per mL or
less) (Table 2). As shown in Table 2, there was no dif-
ference in the levels of systemic inflammatory markers,
and VCAM were seen in subjects with elevated CECs
compared to those with a low CEC number. A step-
wise multiple regression analysis model created for the 44
hemodialysis patients also did not find that these mark-
ers were significant predictors of pre-HD CEC number
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Table 1. Demographic and clinical characteristics of the first and second cohort of hemodialysis patients
First cohort First cohort: First cohort:
as a group Low CEC group High CEC group Second cohort
(N = 29) (N = 10) (N = 19) (N = 44)
Age years 52 ± 15 51 ± 20 53 ± 13 51 ± 14
Male% 52 60 47 45
Ethnicity%
African American 66 60 68 66
Caucasian 24 30 21 30
Hispanic 10 10 11 5
End-stage renal disease etiology %
Diabetes mellitus 34 50 26 34
Hypertension 24 0 37 23
Glomerulonephritis 17 30 5 18
Other 25 20 32 25
ACVD scoreb N (%) c
0 10 (34) 1 (10) 9 (47) 1 (2)
1 6 (21) 5 (50) 1 (5) 16 (36)
2 5 (17) 0 (0) 5 (26) 2 (5)
# of patients classified % of cohort 21 (72) 6 (60) 15 (79) 19 (43)
Time on RRT monthsa 41 (14–98) 37 (12–106) 47 (14–97) 36 (12–78)
Arteriovenous fistula % 66 70 53 55
Pre-hemodialysis SBP mm Hg 150 ± 34 157 ± 41 134 ± 25f 148 ± 27
Pre-hemodialysis DBP mm Hg 79 ± 19 81 ± 18 74 ± 16 80 ± 21
Urea reduction ratio % 74 75 74 74
Hemodialysis dose Kt/V 1.6 ± 0.4 1.7 ± 0.2 1.5 ± 0.5 1.7 ± 0.3
Use of ACEI/ARB % 72 70 74 66
Use of statin therapy % 41 40 42 50
HgbA1c of diabetic patients % 6.1 ± 1.2 5.6 ± 0.9 6.4 ± 1.4 6.1 ± 0.6
Calcium mg/dL 8.6 ± 0.6 8.6 ± 0.5 8.5 ± 0.7 8.9 ± 0.9
Phosphorus mg/dL 4.7 ± 1.8 3.6 ± 1.4 5.3 ± 1.8d 5.6 ± 1.7
Calcium and phosphorus product mg2/dL2 40 ± 15 31 ± 12 45 ± 15f 50 ± 13
Intact parathyroid hormone ng/mLa 290 (132–580) 345 (205–591) 290 (42–610) 244 (132–333)
Hemoglobin g/dL 11.2 ± 0.8 11.3 ± 0.7 11.2 ± 0.8 11.4 ± 1.2
Total weekly erythropoietin dose U/kg/wk a 173 (51–300) 182 (43–309) 183 (62–332) 143 (55–241)
Albumin g/dLa 3.9 (3.5–3.9) 3.9 (3.8–3.9) 3.7 (3.5–3.9) 3.9 (3.6–3.9)
Total cholesterol mg/dL 130 ± 33 113 ± 26 139 ± 33e 149 ± 40
High-density lipoprotein cholesterol mg/dL 48 ± 19 43 ± 15 51 ± 21 51 ± 21
Low-density lipoprotein mg/dL 60 ± 29 47 ± 16 67 ± 31 74 ± 34.3
Triglycerides mg/dL 118 ± 71 141 ± 92 105 ± 56 125 ± 65
Abbreviations are: RRT, renal replacement therapy; Hgb, hemoglobin. Values are expressed as mean ± SD except for athose that are expressed as median (lower
and upper quartile). Conversion factors from conventional to SI units for serum calcium, serum phosphorus, total-cholesterol, and triglycerides (mg/dL to mmol/L) are
0.2495, 0.3229, 0.0259, and 0.0113, respectively, and the conversion factor for serum albumin and hemoglobin (g/dL to g/L) is 10.
bSee Methods for definition of subgroups.
c Twenty-one patients were given ACVD score in the first cohort, and 19 patients were given ACVD score in the second cohort (see Methods section).
dP < 0.05 vs. low CEC group; eP = 0.054 vs. low CEC group; fP = 0.07 vs. low CEC group.
(data not shown). In addition, there was no difference in
the presence/absence of known risk factors between the
two groups (Table 3).
DISCUSSION
The number of CECs is increased in a variety of condi-
tions, and may reflect the activation state of the endothe-
lium [8]. This study is the first to report on the long-term
follow-up of vascular events in hemodialysis patients af-
ter enumeration of CEC number. Previously, we reported
that hemodialysis patients have a higher mean value of
CECs per mL as compared to control patients. In this
study, we used the mean CEC of healthy control patients
from the previous study to divide hemodialysis patients
into two groups, patients with “high” versus “low” num-
ber of CECs. In the ensuing 20 months, all 10 vascular
events occurred in patients that were in the “high” CEC
group. Three of the patients who had an event were in
the active atherosclerotic disease group in the previous
study [7] and would predictably have a higher risk of mor-
tality. The other four patients who had a vascular event
had an elevated CEC with no history of atherosclerotic
disease. Interestingly, no patient previously classified as
having stable ACVD, who as a group had a statistically
lower CEC number, had an event. Despite the small num-
ber of patients in the present study, there is a statistically
significant increased mortality and morbidity from vas-
cular events in hemodialysis patients with a “high” num-
ber of CECs and a trend toward increased cardiovascular
events. To our knowledge, this is the first study to deter-
mine the predictive value of CECs with regard to car-
diovascular morbidity and mortality. However, results of
previous studies were suggestive that CECs could be a
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Fig. 1. Time of onset to first cardiovascular event in patients with high
and low number of CECs. Kaplan-Meier curve showing the time to
onset of first cardiovascular event (. . .) or time to onset of first vascular
(cardiovascular or access-related event; ) ( ) in patients who had
greater than 19 CECs per mL, and in those who had less than or equal
to 19 CECs per mL (- - -). ∗P = 0.035 or ∗∗P = 0.085 by log-rank test
compared to patients with less than or equal to 19 CECs per mL.
Table 2. Relationship between CEC and endothelial and
inflammatory markers
Low CEC group High CEC group
(N = 22) (N = 22) P value
Mean CEC number 11.8 ± 4.4 29.8 ± 12.4 <0.0001
VCAM-1 ng/mL 1961 ± 1309 1646 ± 851 0.55
Serum MCP-1 pg/La 1077 ± 486 1590 ± 2825 0.4
875 (715–1439) 976 (869–1339)
Serum hs-CRP mg/dLa 15.5 ± 19.9 9.6 ± 6.8 0.73
8.38 (3.42–22.6)a 6.19 (4.24–15.1)a
Plasma IL-6 pg/mLa 4.58 ± 7.6 2.05 ± 2.46 0.94
0.55 (0.28–7.8)a 1.77 (0.21–2.8)a
Plasma IL-10 pg/mLa 4.95 ± 3.87 0.92 ± 1.07 0.26
1 (0.5–1) 0.5 (0.5–1)
Statistical analyses were performed using Mann-Whitney U test.
aValues are also given as median (upper-lower quartile).
predictor of cardiovascular events. Patients who suffer
from unstable angina pectoris have an increased num-
ber of CECs compared to patients with stable angina [9],
and CECs are increased in those patient who suffered an
acute myocardial infarction [9, 10]. Also, serial determi-
nation of CEC number demonstrates a decline in CEC
number with improvement of disease processes, such as
ANCA-associated vasculitis [11], sickle cell crisis [8], or
acute myocardial infarction [9]. Our preliminary study
suggests that an elevated CEC number may be a predic-
tor of future cardiovascular morbidity and mortality in
HD patients.
In cohort 2, half of the patients had a “high” CEC num-
ber and half a “low” CEC number; however, there was
no statistical difference in VCAM-1 levels between the
two groups. We also did not find a difference between the
two groups with regard to hs-CRP, IL-6, or IL-10 levels,
nor did we find a correlation between these markers and
Table 3. Cardiovascular risk factors in patients with low and high
CEC numbers in the second cohort
Low CEC High CEC P value
Age 53.3 ± 14.1 49.5 ± 14.6 0.38
Male N (%) 13, (59) 10, (45) 0.54
Total cholesterol 162 ± 46 139 ± 29 0.079
LDL-cholesterol 83 ± 38 65 ± 27 0.11
HDL-cholesterol 53 ± 25 50 ± 15 0.94
Diabetes mellitus N (%) 5, (23) 10, (45) 0.20
Smoker N (%)a 4, (18) 5, (23) 1.0
SBP 149 ± 22 148 ± 32 0.92
DBP 82 ± 19 78 ± 23 0.56
Values are expressed as mean ± SD.
aAny individual currently using tobacco was considered a smoker. There were
no individuals with a remote tobacco history.
CEC number. One explanation for this disparity is that
in the absence of an acute injury there is no increase in
markers of inflammation detected in the serum. Perhaps
in the chronic state, CEC number reflects the level of in-
flammation integrated over days-to-weeks and not one
determination.
In the first cohort, we found a higher calcium phos-
phorous product in the higher CEC group. Although we
are not aware of any published data demonstrating di-
rect endothelial injury of an elevated calcium phospho-
rous product, considering its role in the pathogenesis of
vascular calcifications observed in uremic patients, its as-
sociation with a higher CEC number would seem rea-
sonable. However, evaluating the two cohorts as a whole,
we did not find a correlation between CEC number and
calcium phosphorous product, perhaps emphasizing that
CEC number likely reflects a large number of factors.
The investigation of cardiovascular disease in
hemodialysis patients has found many markers that
correlate with an increased risk of atherosclerotic events.
Previously, blood pressure [12], low serum albumin [13],
anemia [14], hs-CRP [15], and IL-6 [16, 17], among others
[2, 18, 19], have been shown to be related to mortality.
CEC may reflect a unique cardiovascular risk factor. We
envision the endothelium to be an integrator of a variety
of different influences. Forces such as changes in shear
stress [20], elevated glucose [21, 22], and oxidative stress
[23] tend to “activate” the endothelium, while elevated
nitric oxide and heme oxygenase-1 levels may reflect
the inherent ability of an individuals endothelial cell to
resist that activation. CEC number may provide insight
into the product of forces that activate the endothelium
and the forces that act to resist that activation.
Just as CECs are an indicator of endothelial dam-
age, endothelial progenitor cells have increasingly been
viewed as a mechanism of endothelial repair (reviewed in
[24, 25]). Endothelial progenitor cells originate from the
bone marrow, and can differentiate into endothelial cells.
These cells are thought to be important in processes such
as vasculogenesis and endothelial repair (reviewed in
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[24, 25]). Recently, endothelial progenitor cells have been
shown to be inversely proportional to cardiovascular risk
factors [26]. Consistent with this finding, hemodialysis
patients have decreased endothelial progenitor number
and function [27–29]. Thus, the marked vascular disease
seen in hemodialysis patients is likely due to increased en-
dothelial damage, represented by an elevated CEC num-
ber, as well as a decreased ability to repair the endothelial
damage.
CONCLUSION
This study demonstrated that a high CEC number in
hemodialysis patients may be an independent predictor
of cardiovascular events. Since this is a small study, the
findings need to be confirmed in larger prospective study
in hemodialysis patients and in patients at high risk for
vascular events but with normal renal function.
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